Business Wire

OERLIKON

6.6.2024 09:47:29 CEST | Business Wire | Press release

Share
Engineered Solutions Elevate Battery System Safety

Oerlikon presents a full range of innovative customized safety components for Battery Electric Vehicles (BEVs), including pioneering heat shields, gas guidance systems, and cell separators. In the event of a battery fire, they improve the heat protection and electrical and mechanical strength of the batteries, which can save passengers' lives.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240606775871/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Heat resistant parts such as Oerlikon’s high performance customizable heat shields with superior thermal and electrical insulation increase the safety of battery systems. (Image source: OERLIKON)

Thermal runaway poses a significant challenge in high-performance battery systems and can potentially cause extensive vehicle damage or endanger passengers. “Oerlikon is renowned in the automotive market for its engineering expertise and materials innovation. Now we combine carefully engineered cutting-edge heat-resistant materials with an intelligent design to create thermal insulation systems that are redefining industry standards,” said Marcus Spreckels, Head of Technology TIS.

Highly heat-resistance yet thin and lightweight

The portfolio covers all critical components, from heat shields and gas guidance components to cell separators, to address the needs of any battery system and risk level. They are highly heat-resistant, mechanically durable, and yet ultra-light and thin. They insulate the critical high-voltage infrastructure of the batteries electrically and thermally, thus reducing the likelihood of battery fires spreading to the passenger area at an early stage.

From meeting the basic regulatory standards of the UN Electric Vehicle Safety Regulation (GTR 20) and their often more stringent adoption in individual countries, to exceeding the advanced requirements with Stop/Zero TP and limp-home functionality, the components are both versatile and reliable.

No compromise: customized solutions for any requirement

Unlike other manufacturers, Oerlikon does not offer standard products. Marcus Spreckels: "We develop customized solutions in terms of material and design, taking into account the specific safety requirements of each battery concept without compromising on space or weight."

This is where Oerlikon's experience in automotive engineering comes into play: all components are 3D-moldable, so they can be optimally tailored to the design of the battery system and the vehicle, for maximum protection. Each solution is fully customized and ready to install according to individual requirements.

Combining materials science know-how and automotive experience

Oerlikon's thermal insulation solutions across all safety concepts and battery types on the market represent a new standard in the industry. With their deep knowledge in material science, Oerlikon's engineers have created heat-resistant materials with new properties. Furthermore, Oerlikon's decade-long experience in the automotive market allows customers to benefit from customized solutions from a certified manufacturer who is well-versed in the challenges associated with designing vehicles.

Series production for the entire portfolio has started at the Bremen site in the first quarter of 2024.

IATF 16949 certified and using only mica-free materials in its solutions, Oerlikon is committed not only to advancing vehicle safety, but also to environmental responsibility and ethical materials sourcing.

Visit Oerlikon at the Battery Show Europe in Stuttgart, Hall 8, Booth G85! Come by to explore our pioneering multifunctional thermal insulation solutions and meet the developers.

For interviews or more information, please contact us.

About the Oerlikon Surface Solutions Division

Oerlikon is a leading global provider of surface and additive manufacturing solutions and services. The division offers an extensive portfolio of market-leading thin-film, thermal spray and additive manufacturing technologies, equipment, components and materials. Emission reduction in transportation, maximized longevity and performance of tools and components, increased efficiency and intelligent materials are hallmarks of its leadership. Pioneering technology for decades, the division serves customers with standardized and customized solutions across a worldwide network of more than 170 sites in 37 countries.

With its technology brands – Oerlikon Balzers, Oerlikon Metco and Oerlikon AM – the Oerlikon Surface Solutions division focuses on technologies and services that improve and maximize performance, function, design, reliability and sustainability, which are innovative, game-changing advantages for customers in the automotive, aviation, tooling and general industries and in the luxury, medical, semiconductors, power generation and oil & gas markets.

The division is part of the publicly listed Oerlikon Group (SIX: OERL), headquartered in Switzerland, which has 12,600 employees and generated CHF 2.7 billion in revenue in 2023.

For more information see: www.oerlikon.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240606775871/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye